Policy & Regulation
OrganaBio and RxMP Therapeutics partner to advance RMP-402 haemostatic drug product
23 April 2026 - Blood and cell products and services company OrganaBio LLC and RxMP Therapeutics Inc, a late pre-clinical development stage therapeutics company developing novel therapies for the rapi...
Université Laval and Glycovax Pharma agree exclusive global licence to develop innovative galectin-3 inhibitors
23 April 2026 - Canadian biopharmaceutical company Glycovax Pharma Inc announced on Wednesday an exclusive global licence agreement with Université Laval in Quebec, granting Glycovax the rights...
Thryv Therapeutics doses first patients in Wave II clinical study for Long QT Syndrome; THRV-1268 receives FDA Fast Track Designation
23 April 2026 - Thryv Therapeutics Inc, a Canada-based, clinical-stage biotechnology company advancing novel serum glucocorticoid inducible kinase 1 (SGK1) inhibitors for inherited cardiac arrhythmias...
WuXi Biologics receives South Korean certification for commercial manufacturing of bispecific antibody therapeutics
23 April 2026 - WuXi Biologics (HK:2269), a China-based global Contract Research, Development, and Manufacturing Organisation (CRDMO), announced on Thursday that three of its manufacturing facilities ...
PureTech Health reports positive Phase 1b data for LYT-200 in MDS and AML
22 April 2026 - Biotherapeutics company PureTech Health plc reported on Wednesday that its founded entity Gallop Oncology reported positive topline Phase 1b data for LYT-200 in relapsed/refractory hig...
European Commission approves Ojemda as first targeted therapy for relapsed paediatric low-grade glioma
22 April 2026 - French biopharmaceutical company Ipsen (Euronext Paris:IPN) (ADR:IPSEY) announced on Wednesday that the European Commission has granted conditional marketing authorisation for Ojemda (...